Support data for "Targeting myoferlin by 6-shogaol inhibition regulates hyperglycemia-induced retinal vascular dysfunction"

<p dir="ltr">Diabetic retinopathy (DR), a common microvascular complication of diabetes mellitus, remains a leading cause of blindness in middle-aged and elderly populations. The current therapies like intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) and vitrectomy surgery are invasive treatments with risks and discomfort for patients, highlighting the need for the minimally invasive treatment. Our previous study found that 6-shogaol, a bioactive compound from ginger, had the therapeutic potential of alleviating DR, but its molecular mechanism remains unclear. In this study, stable isotope labeling with amino acids in cell culture (SILAC) combined with proteomic sequencing identified myoferlin (MYOF) as the direct target of 6-shogaol. The biochemical studies elucidated that 6-shogaol inhibited the function of MYOF on VEGFR2 activity and reduced the angiogenic responses in the retinal endothelial cells via protein kinase B (Akt)/endothelial nitric oxide synthase (eNOS) pathway. These effects of 6-shogaol were validated in hyperglycemia mouse model. The toxicity experiments and pharmacokinetics study showed that 6-shogaol had a high safety profile. Our findings identified 6-shogaol as a novel, promising, and safe therapeutic candidate through targeting MYOF in alleviating the retinal vascular dysfunction. This dataset includes the data and analysis in this project.</p>